Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 34 (6), 1557-1564

Effects of Bromelain on Motor Responses Following Intra-Medial Forebrain Bundle 6-OHDA Injection in Rat Model of Parkinsonism

Affiliations

Effects of Bromelain on Motor Responses Following Intra-Medial Forebrain Bundle 6-OHDA Injection in Rat Model of Parkinsonism

Temitope Samson Adu et al. Metab Brain Dis.

Abstract

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. The conventional therapeutic measures which include the widely used L-DOPA therapy, are inefficient especially when dopamine loss is severe, and the physical symptoms are full blown. Since neuroinflammation is a core feature of PD, this raised the question of whether early treatment with an anti-inflammatory agent may provide a more efficient intervention for PD. In this study, we investigated the effect of bromelain (an anti-inflammatory drug) on motor responses and dopamine levels in a parkinsonian rat model. Male Sprague-Dawley rats were lesioned stereotaxically with the neurotoxin 6-OHDA. The anti-inflammatory agent, bromelain (40 mg/kg i.p) was used to treat a subset of the rats prior to or 24 h post 6-OHDA lesion. Locomotor activity was assessed after 6-OHDA injection, using the cylinder and step tests. The cortical and striatal concentrations of dopamine were also measured. 6-OHDA injection resulted in marked motor impairment which was prevented by pretreatment with bromelain prior to the lesion. Also, the injection of 6-OHDA into the medial forebrain bundle resulted in a significant reduction in dopamine concentration in the striatum and PFC. Bromelain treatment did not alter the suppression of cortical and striatal dopamine levels. Pre-treatment with bromelain reduced the motor dysfunction in the parkinsonian rat model of PD. The efficacy of treatment with bromelain does not appear to be via preservation of the dopaminergic system. The efficacy of bromelain in 6-OHDA injected rats still remains unclear.

Keywords: 6-OHDA; Bromelain; Dopamine; Parkinson’s disease.

Similar articles

See all similar articles

References

    1. Brain. 2002 Sep;125(Pt 9):2058-66 - PubMed

References

    1. Biomed Pharmacother. 2015 Aug;74:101-10 - PubMed

References

    1. Nat Rev Neurosci. 2012 Sep;13(9):636-50 - PubMed

References

    1. Neurosci Res. 2018 Sep;134:1-9 - PubMed

References

    1. Transl Res. 2013 Mar;161(3):189-95 - PubMed

References

    1. Clin Immunol. 2008 Mar;126(3):345-52 - PubMed

References

    1. Cell. 2009 Apr 3;137(1):47-59 - PubMed

References

    1. Brain Res Bull. 2005 Aug 15;66(3):203-11 - PubMed

References

    1. Neuropharmacology. 2000 Mar 3;39(5):777-87 - PubMed

References

    1. Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5 - PubMed

References

    1. Front Syst Neurosci. 2014 Feb 13;8:16 - PubMed

References

    1. CNS Neurol Disord Drug Targets. 2010 Nov;9(5):526-38 - PubMed

References

    1. Mov Disord. 2014 Apr 15;29(5):597-607 - PubMed

References

    1. Neurosci Lett. 2015 Jun 15;597:132-6 - PubMed

References

    1. Lancet Neurol. 2009 Jan;8(1):67-81 - PubMed

References

    1. Behav Brain Res. 2005 Dec 7;165(2):210-20 - PubMed

References

    1. Neuropharmacology. 2015 Jun;93:308-13 - PubMed

References

    1. Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1365-70 - PubMed

References

    1. Phytomedicine. 2002 Dec;9(8):681-6 - PubMed

References

    1. Clin Immunol. 2008 Jul;128(1):66-74 - PubMed

References

    1. Lancet Neurol. 2003 Jul;2(7):437-45 - PubMed

References

    1. Behav Brain Res. 1990 May 28;38(3):243-61 - PubMed

References

    1. Neurobiol Dis. 2006 Oct;24(1):183-93 - PubMed

References

    1. Evid Based Complement Alternat Med. 2008 Mar;5(1):61-9 - PubMed

References

    1. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2 - PubMed

References

    1. Transl Neurodegener. 2015 Oct 12;4:19 - PubMed

References

    1. Neurology. 1988 Aug;38(8):1285-91 - PubMed

References

    1. Trends Neurosci. 2018 May;41(5):252-254 - PubMed

References

    1. J Neurosci Methods. 2005 May 15;144(1):35-45 - PubMed

References

    1. J Neurosci. 2002 Aug 15;22(16):7006-15 - PubMed

References

    1. Maturitas. 2016 Feb;84:25-31 - PubMed

References

    1. Brain Res Brain Res Rev. 1999 Dec;31(1):6-41 - PubMed

References

    1. J Neurosci. 2001 Jun 15;21(12):4427-35 - PubMed

References

    1. Phytother Res. 2004 May;18(5):343-57 - PubMed

References

    1. J Neurosci. 2004 Aug 18;24(33):7400-9 - PubMed

References

    1. J Neurosci. 2006 Sep 13;26(37):9365-75 - PubMed

References

    1. Cancer Lett. 2003 Feb 20;190(2):151-6 - PubMed

References

    1. Exp Neurol. 2008 Jun;211(2):511-7 - PubMed

References

    1. Ann Neurol. 2010 Jun;67(6):715-25 - PubMed

References

    1. Nat Rev Neurosci. 2001 Aug;2(8):577-88 - PubMed

References

    1. FASEB J. 2005 Apr;19(6):533-42 - PubMed

References

    1. Mediators Inflamm. 2013;2013:271359 - PubMed

References

    1. Front Behav Neurosci. 2011 Oct 24;5:71 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3513-8 - PubMed

References

    1. Pharmacology. 2002 May;65(2):83-6 - PubMed

References

    1. J Neurosci. 1989 Sep;9(9):3326-31 - PubMed

LinkOut - more resources

Feedback